These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 14960257)
1. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Jones L; Hawkins N; Westwood M; Wright K; Richardson G; Riemsma R Health Technol Assess; 2004 Feb; 8(5):iii, xiii-xvi, 1-143. PubMed ID: 14960257 [TBL] [Abstract][Full Text] [Related]
2. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Verma S; Ilersich AL Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745 [TBL] [Abstract][Full Text] [Related]
3. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138 [TBL] [Abstract][Full Text] [Related]
4. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Wagstaff AJ; Ibbotson T; Goa KL Drugs; 2003; 63(2):217-36. PubMed ID: 12515569 [TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169 [TBL] [Abstract][Full Text] [Related]
6. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Ward S; Kaltenthaler E; Cowan J; Brewer N Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497 [TBL] [Abstract][Full Text] [Related]
7. Treatment for anthracycline-pretreated metastatic breast cancer. O'Shaughnessy J; Twelves C; Aapro M Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314 [TBL] [Abstract][Full Text] [Related]
8. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175 [TBL] [Abstract][Full Text] [Related]
9. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Miles D; Vukelja S; Moiseyenko V; Cervantes G; Mauriac L; Van Hazel G; Liu WY; Ayoub JP; O'Shaughnessy JA Clin Breast Cancer; 2004 Oct; 5(4):273-8. PubMed ID: 15507172 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus docetaxel combination therapy. Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; MartÃn M; McKendrick J; Miles D; Twelves C; Hornberger J Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043 [TBL] [Abstract][Full Text] [Related]
12. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247 [TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France]. Priol G; Maurel F; Le Pen C Bull Cancer; 2005 Sep; 92(9):809-16. PubMed ID: 16203271 [TBL] [Abstract][Full Text] [Related]
14. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558 [TBL] [Abstract][Full Text] [Related]
15. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100 [TBL] [Abstract][Full Text] [Related]
16. Lapatinib for the treatment of HER2-overexpressing breast cancer. Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022 [TBL] [Abstract][Full Text] [Related]
17. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713 [TBL] [Abstract][Full Text] [Related]
18. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245 [TBL] [Abstract][Full Text] [Related]
19. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Gelmon K; Chan A; Harbeck N Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739 [TBL] [Abstract][Full Text] [Related]
20. Moving forward with capecitabine: a glimpse of the future. Biganzoli L; Martin M; Twelves C Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]